Background: We aimed to compare trends in CD4+ T-cell recovery after combination antiretroviral therapy (cART) initiation and proportion of patients achieving optimal CD4+ T-cell restoration (counts ≥500 cells/µl) after 12, 36 and 60 months of viral suppression between rapid (RP) and non-rapid progressors (non-RP).
Methods: We included HIV-1 seroconverters (SC) from CASCADE who initiated cART from naïve and achieved viral suppression within the first 6 months. Individuals were classified as RP if they experienced ≥1 CD4+<200 cells/µl within 12 months from SC before cART initiation, non-RP if not. We used piecewise linear mixed-models (slopes changes at months 1 and 18) to model trends in CD4+ T-cell counts and logistic regression to calculate Odds Ratios for optimal restoration. Models were adjusted for sex, risk group, geographical origin, age and HIV-RNA at cART initiation. To compare RP and non-RP with the same baseline CD4+ T-cell count, we applied a post-estimation adjustment procedure to the results of the multivariate linear mixed model and we also fitted multivariate logistic regression models which included an adjustment for CD4+ T-cell count at cART (<100, 100-199, ≥200) initiation.
Results: Of 4,197 individuals, 307 (7.3%) were classified as RP. Median CD4+ T-cell count profiles are shown in Figure 1. Comparison of RP and non-RP with the same baseline CD4+ T-cell count showed that RP experienced a faster CD4+ T-cell increase than non-RP in the first month [difference (95% CI) in mean CD4+ T-cell increase/month (square root scale): 1.87 (1.65; 2.10)], slightly slower increases in months 1-18 [-0.05 (-0.06; -0.03)] and no significant differences in 18-60 [0.001 (-0.010; 0.012)]. Percentage of patients achieving an optimal restoration was significantly lower in RP than non-RP at months 12 (29.0 versus 64.2%) and 36 (46.3% versus 73.2%) but not at month 60 (70.2% versus 72.3%), differences that disappeared after comparing patients with the same CD4+ T-cell count at start of cART: OR (95% CI) 0.79 (0.54; 1.15), 0.79 (0.34; 1.83) and 1.61 (0.58; 4.45) at months 12, 36 and 60, respectively.
Conclusions: Although RP experience faster initial increases of CD4+ T-cell counts that non-RP on suppressive therapy, they are less likely to achieve optimal CD4+ T-cell restoration during the first 36 months after cART, mainly due to their lower CD4+ T-cell counts at cART initiation.